Literature DB >> 10604735

Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas.

S Balesaria1, C Brock, M Bower, J Clark, S K Nicholson, P Lewis, S de Sanctis, H Evans, D Peterson, N Mendoza, M G Glaser, E S Newlands, R A Fisher.   

Abstract

Loss of heterozygosity (LOH) for chromosome 10 is the most frequent genetic abnormality observed in high-grade gliomas. We have used fluorescent microsatellite markers to examine a series of 83 patients, 34 with anaplastic astrocytoma (grade 3) and 49 with glioblastoma multiforme (grade 4), for LOH of chromosome 10. Genotype analysis revealed LOH for all informative chromosome 10 markers in 12 (35%) of patients with grade 3 and 29 (59%) grade 4 tumours respectively, while partial LOH was found in a further eight (24%) grade 3 and ten (20%) grade 4 tumours. Partial LOH, was confined to the long arm (10q) in six and the short arm (10p) in three cases, while alleles from both arms were lost in four cases. Five tumours (one grade 3 and four grade 4) showed heterogeneity with respect to loss at different loci. There was a correlation between any chromosome 10 loss and poorer performance status at presentation (chi2 P = 0.005) and with increasing age at diagnosis (Mann-Whitney U-test P = 0.034) but not with tumour grade (chi2 p= 0.051). A Cox multivariate model for survival duration identified age (proportional hazards (PH), P= 0.004), grade (PH, P= 0.012) and any loss of chromosome 10 (PH, P= 0.009) as the only independent prognostic variables. Specifically, LOH for chromosome 10 was able to identify a subgroup of patients with grade 3 tumours who had a significantly shorter survival time. We conclude that LOH for chromosome 10 is an independent, adverse prognostic variable in high-grade glioma.

Entities:  

Mesh:

Year:  1999        PMID: 10604735      PMCID: PMC2362970          DOI: 10.1038/sj.bjc.6693403

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  The Charing Cross Hospital experience with temozolomide in patients with gliomas.

Authors:  E S Newlands; S M O'Reilly; M G Glaser; M Bower; H Evans; C Brock; M H Brampton; I Colquhoun; P Lewis; J M Rice-Edwards; R D Illingworth; P G Richards
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

2.  Diploid hydatidiform moles with fetal red blood cells in molar villi. 2--Genetics.

Authors:  R A Fisher; F J Paradinas; B A Soteriou; M Foskett; E S Newlands
Journal:  J Pathol       Date:  1997-02       Impact factor: 7.996

3.  Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value.

Authors:  J M Cunningham; D W Kimmel; B W Scheithauer; J R O'Fallon; P J Novotny; R B Jenkins
Journal:  J Neurosurg       Date:  1997-01       Impact factor: 5.115

4.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

5.  Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival.

Authors:  N G Rainov; K U Dobberstein; H Bahn; H J Holzhausen; C Lautenschläger; V Heidecke; W Burkert
Journal:  J Neurooncol       Date:  1997-10       Impact factor: 4.130

6.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

7.  Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas.

Authors:  A Waha; A Baumann; H K Wolf; R Fimmers; J Neumann; D Kindermann; K Astrahantseff; I Blümcke; A von Deimling; U Schlegel
Journal:  J Neurosurg       Date:  1996-10       Impact factor: 5.115

8.  Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation.

Authors:  A Zhu; J Shaeffer; S Leslie; P Kolm; A M El-Mahdi
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-03-01       Impact factor: 7.038

9.  Necrosis as a prognostic factor in glioblastoma multiforme.

Authors:  F G Barker; R L Davis; S M Chang; M D Prados
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

10.  MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.

Authors:  P Korkolopoulou; P Christodoulou; K Kouzelis; M Hadjiyannakis; A Priftis; G Stamoulis; A Seretis; E Thomas-Tsagli
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  14 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

Review 2.  Biology, genetics and imaging of glial cell tumours.

Authors:  C Walker; A Baborie; D Crooks; S Wilkins; M D Jenkinson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

3.  Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization.

Authors:  Yukiko Nakahara; Tetsuya Shiraishi; Hiroaki Okamoto; Toshihiro Mineta; Tsuyoshi Oishi; Kohsuke Sasaki; Kazuo Tabuchi
Journal:  Neuro Oncol       Date:  2004-10       Impact factor: 12.300

Review 4.  Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Authors:  Nadia Senhaji; Asmae Squalli Houssaini; Salma Lamrabet; Sara Louati; Sanae Bennis
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

5.  Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas.

Authors:  Kinya Terada; Takashi Tamiya; Shigeru Daido; Hirokazu Kambara; Hiroaki Tanaka; Yasuhiro Ono; Kengo Matsumoto; Sachio Ito; Mamoru Ouchida; Takashi Ohmoto; Kenji Shimizu
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

6.  The importance of genomic copy number changes in the prognosis of glioblastoma multiforme.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; Hamza Müslümanoğlu; Ramazan Durmaz; Erhan Cosan; Metin Ant Atasoy; Nurettin Başaran; Eşref Tel
Journal:  Neurosurg Rev       Date:  2003-07-04       Impact factor: 3.042

7.  Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers.

Authors:  Jonathan M Dreyfuss; Mark D Johnson; Peter J Park
Journal:  Mol Cancer       Date:  2009-09-04       Impact factor: 27.401

8.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials.

Authors:  Daniel J Brat; Wendy F Seiferheld; Arie Perry; Elizabeth H Hammond; Kevin J Murray; Alan R Schulsinger; Minesh P Mehta; Walter J Curran
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

9.  Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases.

Authors:  M Karoui; C Tresallet; C Julie; U Zimmermann; F Staroz; A Brams; C Muti; C Boulard; A-M Robreau; H Puy; R Malafosse; C Penna; F-R Pruvot; J P Thiery; C Boileau; P Rougier; B Nordlinger; F Radvanyi; B Franc; H Hofmann-Radvanyi
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

10.  Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas.

Authors:  Jingmei Liu; Huimei Lu; Hiroko Ohgaki; Adrian Merlo; Zhiyuan Shen
Journal:  BMC Cancer       Date:  2009-08-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.